NASDAQ : EAC
$0.01 (0.09%)
| Source | Headline |
|---|---|
|
Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers
Positive high-level results from the CLARITY-Gastric01 global Phase III trial showed that sonesitatug vedotin (Sone-Ve) demonstrated a statistically significan gurufocus.com - 2026-07-27 08:00:00 |
|
Newmont's Red Chris Block Cave Project Receives Major Regulatory Approvals
Newmont Corporation (NYSE: NEM, ASX: NEM, PNGX: NEM) (âNewmontâ) welcomes the Province of British Columbia's approval of key regulatory authorizations for gurufocus.com - 2026-06-19 13:00:00 |
|
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
[url="]KalVista Pharmaceuticals[/url], Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged gurufocus.com - 2026-05-28 08:00:00 |